Preliminary data suggests potential use beyond early AKI diagnosis for NGAL biomarker
July 17, 2024 11:50 ET
|
BioPorto A/S
July 17, 2024 News Release Preliminary data suggests potential use beyond early AKI diagnosis for NGAL biomarker COPENHAGEN, Denmark and BOSTON, MA, USA, July 17, 2024, (GLOBE...
Results from Clinical Studies Highlight the Efficacy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Predicting Acute Kidney Injury
July 11, 2024 11:15 ET
|
BioPorto A/S
July 11, 2024 News Release Results from Clinical Studies Highlight the Efficacy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Predicting Acute Kidney Injury COPENHAGEN, Denmark and...
Grant of Warrants
July 04, 2024 11:54 ET
|
BioPorto A/S
4 July 2024Announcement no. 17 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, July 4, 2024 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”)...
BioPorto confirms market acceptance of NGAL products with US standing order.
July 01, 2024 11:30 ET
|
BioPorto A/S
July 1, 2024 News Release BioPorto confirms market acceptance of NGAL products with US standing order. COPENHAGEN, Denmark and BOSTON, MA, USA, July 1, 2024, (GLOBE NEWSWIRE) --...
Managers’ transactions
June 24, 2024 03:55 ET
|
BioPorto A/S
June 24, 2024Announcement no. 16 Managers’ transactions In connection with the completion of BioPorto A/S’ directed issue as described in company announcement no. 15, BioPorto A/S has...
Changes of number of shares and votes in BioPorto A/S
June 24, 2024 03:52 ET
|
BioPorto A/S
June 24, 2024Announcement no. 15 Changes of number of shares and votes in BioPorto A/S. Completion of share capital increase The Board of Directors of BioPorto A/S (“BioPorto” og the...
Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.4 million, corresponding to USD 11.7 million, to BioPorto A/S.
June 18, 2024 02:14 ET
|
BioPorto A/S
June 18, 2024Announcement no. 14 Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.4 million, corresponding to USD 11.7 million, to BioPorto A/S. COPENHAGEN,...
BioPorto A/S initiates a private placement of 50,000,000 new shares at market price.
June 17, 2024 13:04 ET
|
BioPorto A/S
June 17, 2024Announcement no. 13 THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA,...
BioPorto A/S Appoints Chief Financial Officer
May 30, 2024 08:17 ET
|
BioPorto A/S
May 30, 2024Announcement no. 12 BioPorto A/S Appoints Chief Financial Officer BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced the appointment of Niels Høy Nielsen as its new...
First Quarter 2024: Strong growth in US sales of The NGAL Test
May 08, 2024 02:21 ET
|
BioPorto A/S
May 8, 2024 Announcement no. 11 First Quarter 2024: Strong growth in US sales of The NGAL Test COPENHAGEN, Denmark and BOSTON, MA, USA, May 8, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S CVR-no....